P

    Protagonist Therapeutics Inc (PTGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $147.75
    +3.42 (+2.37%)

    Market Cap: $9.34B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    +43.47%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$2.49
    Range$0.13 - $3.71
    10 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$2.24-10.1%
    60d ago$2.24-10.1%
    30d ago$2.25-9.4%
    7d ago$2.47-0.5%
    Current$2.49
    Revenue Consensus
    $239M
    Range$95M - $292M
    11 analysts
    Dec 31, 2026
    EPS Consensus$1.09
    Range$-0.14 - $2.34
    11 analysts
    Revenue Consensus
    $59M
    Range$-50379250 - $110M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.09---
    Sep 26EST
    		-$2.49---
    Jun 26
    		$2.29$2.11+8.53%Beat+516.4%
    Mar 26
    		$0.05N/A+107.69%Beat+126.3%
    Dec 25
    		$-0.69$-0.34-102.76%Miss-134.8%
    Sep 25
    		$-0.62$-0.64+3.13%Beat-14.8%
    Jun 25
    		$-0.55$-0.52-5.77%Miss-10.0%
    Mar 25
    		$-0.19$0.11-272.73%Miss-105.8%
    Dec 24
    		$1.98$0.25+692.00%Beat+350.0%
    Sep 24
    		$-0.54$-0.53-1.89%Miss+6.9%
    Jun 24
    		$-0.50$-0.41-21.95%Miss+26.5%
    Mar 24
    		$3.26$1.60+103.75%Beat+586.6%
    Dec 23
    		$0.44$-0.03+1566.67%Beat+163.8%
    Sep 23
    		$-0.58$-0.70+17.14%Beat+9.4%
    Jun 23
    		$-0.68$-0.66-3.03%Miss+19.0%
    Mar 23
    		$-0.67$-0.70+4.29%Beat-55.8%
    Dec 22
    		$-0.69$-0.64-7.81%Miss+10.4%
    Sep 22
    		$-0.64$-0.85+24.71%Beat+8.6%
    Jun 22
    		$-0.84$-0.98+14.29%Beat-21.7%
    Mar 22
    		$-0.43$-0.60+28.33%Beat+20.4%
    Dec 21
    		$-0.77$-0.78+1.28%Beat-60.4%
    Sep 21
    		$-0.70$-0.66-6.06%Miss-233.3%
    Jun 21
    		$-0.69$-0.53-30.19%Miss-21.1%
    Mar 21
    		$-0.54$-0.56+3.57%Beat+25.0%
    Dec 20
    		$-0.48$-0.48+0.00%Beat+23.8%
    Sep 20
    		$-0.21N/A+62.50%Beat+65.6%
    Jun 20
    		$-0.57$-0.58+1.72%Beat+51.7%
    Mar 20
    		$-0.72$-0.69-4.35%Miss-24.1%
    Dec 19
    		$-0.63$-0.70+10.00%Beat-10.5%
    Sep 19
    		$-0.61$-0.73+16.44%Beat-60.5%
    Jun 19
    		$-1.18$-0.27-337.04%Miss-187.8%
    Mar 19
    		$-0.58$-0.59+1.69%Beat-61.1%
    Dec 18
    		$-0.57$-0.47-21.28%Miss-280.0%
    Sep 18
    		$-0.38$-0.33-15.15%Miss-31.0%
    Jun 18
    		$-0.41$-0.29-41.38%Miss+53.9%
    Mar 18
    		$-0.36$-0.24-50.00%Miss+57.1%
    Dec 17
    		$-0.15N/A+57.14%Beat+77.6%
    Sep 17
    		$-0.29N/A+52.46%Beat+66.7%
    Jun 17
    		$-0.89$-0.81-9.88%Miss-
    Mar 17
    		$-0.84$-0.59-42.37%Miss-
    Dec 16
    		$-0.67$-0.52-28.85%Miss-
    Sep 16
    		$-0.87$-0.64-35.94%Miss-

    Key Metrics

    Valuation
    P/E Ratio143.45EV/EBITDA148.58x
    Price/FCF74.60xFCF Yield1.34%
    Profitability
    Profit Margin29.40%Operating Margin74.40%
    ROE11.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio21.71xQuick Ratio21.71x
    Trading Statistics
    Beta1.79Avg Volume496.91K
    52-Week High$160.8152-Week Low$54.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$151.57
    SMA 20$149.81
    SMA 50$138.83
    SMA 200$104.81
    EMA 10$149.77
    EMA 20$148.11
    EMA 50$138.33
    EMA 200$108.31

    MACD

    Line: 3.41Signal: 5.01Hist: -1.59

    ADX

    ADX: 29.7+DI: 18.6-DI: 18.3

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down12.0
    PSAR$157.32

    Bollinger Bands

    Upper Band$161.62
    Lower Band$138.01
    %B Position1576%(Upper)
    Band Width0.41

    RSI (14-Day)

    Neutral
    52.3

    Momentum Oscillators

    Stoch %K19.4
    Stoch %D26.8
    Williams %R-69.5
    ROC (10d)-6.9%
    Momentum-10.87
    CCI (20d)-49.4
    MFI (14d)54.1

    Volatility Measures

    ATR (14d)$5.88(4.0%)
    StdDev (20d)5.90
    Hist Vol38.8%(Moderate)

    Volume Flow

    VWAP$146.35
    OBV23.4M
    AD Line25.4M
    CMF (20d)0.066

    Volume Metrics

    Avg Vol (20d)499.2K
    Vol Ratio1.1x
    VWMA (20d)$149.68

    Pivot Points

    R3$152.90
    R2$150.42
    R1$147.38
    Pivot Point$144.90
    S1$141.86
    S2$139.38
    S3$136.34

    Advanced Oscillators

    TSI16.93
    Ultimate Osc52.7
    KST115.96

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$213.47M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M$4.67M$4.17M$254.95M$60.00M$0
    Cost of Revenue$0$0$376,000$0$0$0$604,000$0$0$0$832,000$0
    Gross Profit$213.47M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M$4.67M$4.17M$254.95M$60.00M$0
    Operating Expenses$54.71M$60.02M$57.79M$51.13M$47.59M$47.63M$43.86M$46.13M$42.96M$48.64M$36.95M$38.33M
    R&D$42.06M$46.74M$46.36M$40.00M$37.04M$35.89M$34.90M$35.97M$33.52M$33.73M$28.90M$30.66M
    SG&A$12.65M$13.28M$11.43M$11.13M$10.55M$11.74M$8.95M$10.16M$9.44M$14.91M$8.05M$7.66M
    Operating Income$158.77M$-3,648,000$-50,355,000$-46,421,000$-42,041,000$-19,310,000$126.78M$-41,453,000$-38,793,000$206.31M$23.05M$-38,326,000
    Interest Income$6.43M$5.88M$6.76M$7.05M$7.41M$7.57M$6.85M$7.68M$7.40M$4.38M$4.24M$4.25M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$165.11M$2.28M$-43,718,000$-39,339,000$-34,599,000$-11,655,000$133.66M$-33,630,000$-31,292,000$210.67M$27.34M$-34,105,000
    Income Tax Expense$2.27M$-1,502,000$666,000$0$172,000$0$1.99M$-420,000$-676,000$3.33M$0$0
    Net Income$162.85M$3.78M$-44,384,000$-39,339,000$-34,771,000$-11,655,000$131.67M$-33,210,000$-30,616,000$207.34M$27.34M$-34,105,000
    EBITDA$158.04M$-4,213,000$-51,439,000$-47,711,000$-43,615,000$-21,278,000$124.17M$-43,919,000$-40,117,000$204.91M$20.24M$-38,536,000
    EBIT$158.69M$-3,595,000$-50,479,000$-46,388,000$-42,005,000$-19,228,000$126.81M$-41,312,000$-38,696,000$206.29M$23.09M$-38,357,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PTGX

    News

    EFG International AG Buys Shares of 40,501 Protagonist Therapeutics, Inc. $PTGX

    EFG International AG has acquired a new position in Protagonist Therapeutics (NASDAQ:PTGX), purchasing 40,501 shares valued at approximately $4.96 million during the second quarter. Other institutional investors like BlackRock Inc., Johnson & Johnson, Janus Henderson Group PLC, Wellington Management Group LLP, and Vanguard Group Inc. have also significantly modified their holdings in the company. Protagonist Therapeutics' stock performance, strong quarterly earnings, and "Moderate Buy" consensus rating from analysts indicate positive sentiment, though insider selling by CEO Dinesh V. Ph D. Patel and Director William D. Waddill was noted.

    MarketBeat•8/26/26•
    Bullish

    Elmind Capital LP Invests $4.66 Billion in Protagonist Therapeutics, Inc. $PTGX

    Elmind Capital LP has acquired a new stake of 38,000 shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), valued at approximately $4.66 billion, making it their 21st largest holding. Other institutional investors have also adjusted their positions in PTGX, while company insiders have sold a significant number of shares recently. Analysts maintain a "Moderate Buy" consensus rating for Protagonist Therapeutics, with several firms raising their price targets.

    MarketBeat•8/26/26•
    Bullish

    Castleark Management LLC Buys Shares of 50,570 Protagonist Therapeutics, Inc. $PTGX

    Castleark Management LLC has acquired 50,570 shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the second quarter, valued at approximately $6.2 million. This move makes Castleark Management LLC own about 0.08% of the company. Other institutional investors have also made changes to their positions in PTGX, while company insiders have sold a significant number of shares recently.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    ADAR1 Capital Management LLC Makes New $117.78 Million Investment in Protagonist Therapeutics, Inc. $PTGX

    ADAR1 Capital Management LLC has made a new significant investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), acquiring 960,863 shares valued at approximately $117.78 million, making it their second-largest position. Other institutional investors and hedge funds, including Johnson & Johnson and NEXTBio Capital Management LP, have also recently adjusted their stakes in the company. Protagonist Therapeutics has received a "Moderate Buy" average rating from analysts, with a price target of $140.53, and has shown strong financial performance with a significant revenue increase and insiders recently selling shares.

    MarketBeat•8/26/26•
    Bullish

    Protagonist Therapeutics, Inc. $PTGX Shares Bought by Algert Global LLC

    Algert Global LLC increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 11.8% during the second quarter, owning 87,698 shares valued at $10.75 million. Other institutional investors like BlackRock Inc., Johnson & Johnson, Janus Henderson Group PLC, Wellington Management Group LLP, and Vanguard Group Inc. also made significant changes to their holdings. The article also details recent analyst upgrades, insider stock sales by Director William D. Waddill and CEO Dinesh V. Ph D. Patel, and the company's recent financial performance, including its Q2 earnings beat.

    MarketBeat•8/26/26•
    Neutral

    Frequently Asked Questions About PTGX

    Does PTGX pay dividends?
    Protagonist Therapeutics Inc (PTGX) does not currently pay a regular dividend.
    What is PTGX's P/E ratio?
    Protagonist Therapeutics Inc has a price-to-earnings (P/E) ratio of 143.45.
    What is PTGX's market cap?
    Protagonist Therapeutics Inc (PTGX) has a market capitalization of $9.34B with a current stock price of $147.75.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In